DOI: 10.12890/2024_004887
Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma
Authors
brendarodriguezarroyo@gmail.com
Keywords
ALK fusion, non-small cell lung carcinoma, alectinib, next-generation sequencingAbstract
Introduction: Lung cancer is the second most common cancer worldwide and the leading cause of cancer deaths; non-small cell lung cancer (NSCLC) constitutes about 85% of lung cancer cases, with ALK fusions representing 3–6% of them. The SQSTM1-ALK fusion is a rare finding in NSCLC, accounting for only 1.1% of ALK rearrangements. We present a case of lung adenocarcinoma with documentation of SQSTM1-ALK fusion that showed a partial response to alectinib.
Case description: This case details the clinical course of a 71-year-old, non-smoking woman with no significant medical history who presented with confusion, aphasia and multiple cerebral lesions detected on imaging. Further investigations revealed a stage IV lung adenocarcinoma with metastases to the brain and adrenal gland. Molecular profiling identified a rare SQSTM1-ALK fusion mutation alongside other genetic abnormalities, including low programmed death-ligand 1 expression and ROS1 kinase protein presence. Treatment with alectinib, initiated based on the identified ALK fusion, resulted in significant tumour regression in the lungs and complete resolution of the adrenal mass, as evidenced by follow-up imaging and clinical assessments.
Conclusion: This case highlights the efficacy of alectinib in treating rare ALK fusion variants in and underscores the importance of comprehensive molecular profiling in guiding targeted therapy decisions.
References
- Cognigni V, Pecci F, Lupi A, Pinterpe G, De Filippis C, Felicetti C, et al. The landscape of ALK-rearranged non-small cell lung cancer: a comprehensive review of clinicopathologic, genomic characteristics, and therapeutic perspectives. Cancers (Basel) 2022;14:4765.
- Takeuchi K, Soda M, Togashi Y, Ota Y, Sekiguchi Y, Hatano S, et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 2011;96:464–467.
- Iyevleva AG, Raskin GA, Tiurin VI, Sokolenko AP, Mitiushkina NV, Aleksakhina SN, et al. Novel ALK fusion partners in lung cancer. Cancer Lett 2015;362:116–121.
- Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 2022;40:611–625.
- Desai A, Mohammed T, Rakshit S, Krull J. 21P The landscape of ALK alterations in non-small cell lung cancer. J Thorac Oncol 2021;16:S707.
- Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. Mol Cell 2009;34:259–269.
- Lee ATM, Ou SI. ALESIA 5-year update: alectinib at 600 mg twice daily gives lorlatinib a run for its money in Asia. Lung Cancer (Auckl) 2023;14:71–78.
- Xiang Y, Zhang S, Fang X, Jiang Y, Fang T, Liu J, et al. Therapeutic advances of rare ALK fusions in non-small cell lung cancer. Curr Oncol 2022;29:7816–7831.
- Sunga CGG, Higgins MS, Ricciotti RW, Liu YJ, Cranmer LD. Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib. Cancer Rep (Hoboken) 2023;6:e1792.
- d’Amore ES, Visco C, Menin A, Famengo B, Bonvini P, Lazzari E. STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target. Am J Surg Pathol 2013;37:780–786.
